*DHA: docosahexaenoic acid. Beneficial effects start at 250 mg of DHA a day.

Daily dietary supplement containing HIGH CONCENTRATION omega-3:

  • DHASCC 275 mg
  • Rapid bioavailability capsules

Om3gafortSCC uses HIGH CONCENTRATION Omega-3 polyunsaturated fatty acids EPA/DHA, EFFICACY, PURITY and SAFETY obtained with an ENVIRONMENTALLY FRIENDLY technology known as Supercritical Concentration (SCC).

Om3gafortSCC DHASCC uses LiqFillCapsTM hard capsules that facilitate better absorption of DHA in the body.

LiqFillCapsTM are an innovative technological concept that provide effective solutions for many of the challenges faced by the pharmaceutical and neutraceutical industry. In particular those related to the low solubility of bioactive ingredients and agents, thus obtaining increased oral bioavailability and absorption.



Daily dose: 2 capsules. % DV based on daily dose.

1 capsule 2 capsule % DV*
Energy value in kcal 4,8 kcal 9,6 kcal **
Energy value in kJ 20,00 kJ 40,0 kJ **
Protein  81 mg 162 mg **
Carbohydrates 30 mg 60 mg **
Total Fat / Lipids 482 mg 964 mg **
Polyunsaturated fat 467 mg 934 mg **
Omega-3 fatty acids# 325 mg 650 mg **
EPA (eicosapentaenoic acid) 25 mg 50 mg **
DHA (docosahexaenoic acid) 275 mg 550 mg **

*Recommended daily amount as per Directive 2008/100/CE of 28 October 2008.
**Daily value not established.
#Guaranteed minimum quantity of the active ingredient expressed in mg. Percentages calculated on the basis of the minimum quantity expressed in mg are subject to variation.


Fish Oil: (minimum 55% DHA, minimum 5% EPA), Gelatin, Emulsifier: Soya lecithin, Antioxidants: natural mixed tocopherols, Color Additives (E132).

Greater concentration, greater efficacy

Children and adolescents:
  1. Auestad N, Scott DT, Janowsky JS, Jacobsen C, Carroll RE, Montalto MB, Halter R, Qiu W, Jacobs JR, Connor WE, Connor SL, Taylor JA, Neuringer M, Fitzgerald KM, Hall RT. Visual, cognitive, and language assessments at 39 months: a follow-up study of children fed formulas containing long-chain polyunsaturated fatty acids to 1 year of age. Pediatrics. 2003 Sep;112(3 Pt 1):e177-83.
  1. Stevens L, Zhang W, Peck L, Kuczek T, Grevstad N, Mahon A, Zentall SS, Arnold LE, Burgess JR. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids. 2003 Oct;38(10):1007-21.
  1. McNamara RK. Evaluation of docosahexaenoic acid deficiency as a preventable risk factor for recurrent affective disorders: current status, future directions, and dietary recommendations. Prostaglandins Leukot Essent Fatty Acids. 2009 Aug-Sep;81(2-3):223-31. Epub 2009 Jun 9.
  1. Freemantle E, Vandal M, Tremblay-Mercier J, Tremblay S, Blachère JC, Bégin ME, Brenna JT, Windust A, Cunnane SC. Omega-3 fatty acids, energy substrates, and brain function during aging. Prostaglandins Leukot Essent Fatty Acids. 2006 Sep;75(3):213-20.

el contenido de esta página requiere una versión más reciente de adobe flash player.

Obtener adobe flash player

LiqFillCapsTM are an innovative technological concept that provides an efficient solution to the many challenges the pharmaceutical and nutraceutical industries face, in particular those due to the low solubility of active ingredients and bioactive agents, thereby helping to achieve an increase in both oral bioavailability and absorption.